10月15日，Veeva Systems盘中上涨3.59%，报308.93美元/股，成交额1.47亿美元。
推动股价异动的最新消息是，IQVIA宣布在其临床开发研究中选用Veeva四款企业级标准应用，包括Clinical Trial Management System、eTMF、Study Startup和Site Connect，以提升临床试验效率与协同。
该合作进一步强化了Veeva在生命科学研发云软件领域的渗透。此前公司还披露，DQS平台已服务超100万名临床试验受试者、覆盖逾1000项研究；叠加8月季度营收9.28亿美元、调整后每股收益2.35美元，均高于预期，基本面与订单进展形成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.